"If we witness good revenue growth it should see better...

"If we witness good revenue growth it should see better margins".

Well, yes, if MYX increase their volumes of generic sales they benefit from the efficiency of dispersing production costs against a larger pool of revenue from generics. But that does not really inform on the negative effect of price erosion eating into MYX revenues in the generic market.

If some newly consolidated buying groups try to exert yet more pressure on the prices of some of MYX's generic lines, I wonder just how far that can go? Or if a U.S. President perceives some political mileage in embarking on a crusade against the price of generic pharmaceuticals, can that deal MYX a mighty blow?

I suppose part of the answer might be found by looking at MYX's specific products and whether there are ready alternatives from competing manufacturers if a buying group wants to haggle with prices. I think it was said in another thread that an analyst considers that MYX operates in a bit of a niche (presumably, he was particularly referring to MYX's portfolio of dermatological products).